Evidence map›Paper›PMID 33830342›Full record

ArticleInternational journal of clinical oncology2021

Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting.

Shin Kariya, Yasushi Shimizu, Nobuhiro Hanai, Ryuji Yasumatsu, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Masafumi Yoshida, Kenji Hanyu, Tsutomu Ueda and 16 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03569436 (Efficacy and Safety of Nivolumab in Recurrent or Metastatic Head and Neck Cancer), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03569436 completednot on this map

Efficacy and Safety of Nivolumab in Recurrent or Metastatic Head and Neck Cancer (HNC) Patients - Japanese Real-world Data Through Clinical Chart Review

TypeobservationalSponsorBristol-Myers SquibbRan2018 to 2020Enrolled262ConditionsCancer of Head and Neck, Cancer of the Head, Cancer of the Neck
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 1 country.

Shin KariyaDepartment of Otolaryngology, Head and Neck Surgery, Okayama University Hospital, Okayama, Japan.
Yasushi ShimizuDepartment of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Ryuji YasumatsuDepartment of Otolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tomoya YokotaDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
Takashi FujiiDepartment of Head and Neck Surgery, Osaka International Cancer Institute, Osaka, Japan.
Kiyoaki TsukaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Masafumi YoshidaDepartment of Otorhinolaryngology and Head and Neck Surgery, The University of Tokyo Hospital, Tokyo, Japan.
Kenji HanyuHead and Neck Oncology Center, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.
Tsutomu UedaDepartment of Otorhinolaryngology, Head and Neck Surgery, Hiroshima University Hospital, Hiroshima, Japan.
Hitoshi HirakawaDepartment of Otorhinolaryngology, Head and Neck Surgery, University of the Ryukyu Hospital, Nishihara, Japan.
Shunji TakahashiDepartment of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Takeharu OnoDepartment of Otolaryngology, Head and Neck Surgery, Kurume University Hospital, Kurume, Japan.
Daisuke SanoDepartment of Otolaryngology, Head and Neck Surgery, Yokohama City University Hospital, Yokohama, Japan.
Moriyasu YamauchiDepartment of Otolaryngology, Head and Neck Surgery, Saga University Hospital, Saga, Japan.
Akihito WatanabeDepartment of Otolaryngology, Head and Neck Surgery, Keiyukai Sapporo Hospital, Sapporo, Japan.
Koichi OmoriDepartment of Otolaryngology, Head and Neck Surgery, Kyoto University Hospital, Kyoto, Japan.
Tomoko YamazakiDivision of Head and Neck Cancer Oncology, Miyagi Cancer Center, Sendai, Japan.
Nobuya MondenDepartment of Head and Neck Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Naomi KudoDepartment of Otorhinolaryngology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Makoto AraiDepartment of Medical Oncology, Chiba University Hospital, Chiba, Japan.
Shuji YonekuraDepartment of Otorhinolaryngology, Head and Neck Surgery, Chiba University Hospital, Chiba, Japan.
Takahiro AsakageDepartment of Head and Neck Surgery, Tokyo Medical and Dental University Medical Hospital, Tokyo, Japan.
Akinori FujiwaraMedical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Takayuki YamadaJapan Medical and Development, Bristol-Myers Squibb K.K., Tokyo, Japan.
Akihiro HommaDepartment of Otolaryngology, Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita15 Nishi7, Kita-Ku, Sapporo, Hokkaido, 060-8638, Japan. ak-homma@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0003-1488-0646
Chiba University Hospital · JPAichi Cancer Center · JPBristol-Myers Squibb (Japan) · JPHirosaki University · JPHiroshima University Hospital · JPHokkaido University · JPKeiyukai Sapporo Hospital · JPKurume University Hospital · JPKyoto University Hospital · JPKyushu University · JPMita Hospital · JPMiyagi Prefectural Hospital Organization · JPOkayama University Hospital · JPOno Pharmaceutical (Japan) · JPOsaka International Cancer Institute · JPSaga University · JPSapporo Medical University · JPShikoku Cancer Center · JPShizuoka Cancer Center · JPThe Cancer Institute Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo examine the effect of prior use of cetuximab and neck dissection on the effectiveness of nivolumab, we conducted a large-scale subgroup analysis in Japanese patients with recurrent/metastatic head and neck cancer.

methodsData on the effectiveness of nivolumab were extracted from patient medical records. All patients were analyzed for effectiveness by prior cetuximab use. In the analyses for prior neck dissection, only patients with locally advanced disease were included.

resultsOf 256 patients analyzed, 155 had received prior cetuximab. Nineteen of 50 patients with local recurrence underwent neck dissection. The objective response rate was 14.7 vs 17.2% (p = 0.6116), median progression-free survival was 2.0 vs 3.1 months (p = 0.0261), and median overall survival was 8.4 vs 12 months (p = 0.0548) with vs without prior cetuximab use, respectively. The objective response rate was 23.1 vs 25.9% (p = 0.8455), median progression-free survival was 1.8 vs 3.0 months (p = 0.6650), and median overall survival was 9.1 vs 9.9 months (p = 0.5289) with vs without neck dissection, respectively.

conclusionsThese findings support the use of nivolumab for patients with recurrent/metastatic head and neck cancer regardless of prior cetuximab use or neck dissection history. TRIAL REGISTRATION NUMBER: UMIN-CTR (UMIN000032600), Clinicaltrials.gov (NCT03569436).

Indexed as

CetuximabImmune microenvironmentNeck dissectionNivolumabRecurrent or metastatic head and neck cancer

Identifiers

PMID33830342
PMCPMC8134300
OpenAlexW3142872987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.